Mean increases from baseline to Week 48 in total cholesterol (+60 mg/dL in each group) and triglycerides (+85 mg/dL in the LPV/r+SQV group and +64 mg/dL in the LPV/r+ZDV/3TC group) were similar between groups. Most subjects remained at Grade 0–1 total cholesterol or triglyceride levels in both treatment groups through 48 weeks.

Cholesterol increases included increases in both HDL cholesterol and LDL cholesterol. In the LPV/r+SQV group, the LDL-HDL cholesterol ratio was similar at baseline (3.5) and Week 48 (3.6); in the LPV/r+ZDV/3TC group, the ratio increased from 2.9 to 3.6. However, neither change was statistically significantly different from baseline, and the difference between groups was not significant.

No subjects were initiated on lipid lowering agents during the 48-week study period.

**SUMMARY**

In this pilot study, a regimen of LPV/r+SQV demonstrated similar efficacy based on the proportion of subjects with HIV-1 RNA <50 copies/mL and change from baseline in CD4+ T-cell counts through 48 weeks, compared to those receiving a standard triple regimen of LPV/r+ZDV/3TC.

Similar frequencies and types of moderate or severe adverse events were noted between the 2 treatment groups.

The only grade 3+ lab abnormalities noted in >1 subject were AST and ALT elevations, which occurred at similar rates in hepatitis coinfected subjects in both treatment groups.

A similar degree of total cholesterol and triglyceride elevation was noted in both treatment groups through 48 weeks.

No change in fasting glucose was noted in either treatment group in subjects treated for 48 weeks.

**CONCLUSIONS**

The dual PI (NRTI-sparing) regimen of LPV/r plus saquinavir had similar efficacy and safety compared to a LPV/r-based standard combination antiretroviral regimen, with no more frequent lipid abnormalities and no elevation of fasting blood glucose over time.

Although the small sample size limits the ability to discern differences between treatment groups, additional controlled studies of dual PI regimens may be considered to further assess possible metabolic benefits over the long term in treatment-naïve patients and the ability to treat NRTI-resistant HIV-1 in treatment-experienced patients. It may also be of greater interest to assess the potency, tolerability, and safety of dual PI combinations as new dosages forms become available.

**REFERENCES**

3. Staszewski S, Gallant JE, Poznanski AK et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 36-week preliminary interim results. 10th CROI, Boston, MA, 2003; Poster 554c.

**ACKNOWLEDGMENTS**

Study 384 Subjects

Study 384 Clinical Site Coordinators:

- Man Ming Tse – Pacific Horizon Medical Group, San Francisco, CA
- Richard Gamble – University of Ottawa at The Ottawa Hospital, Ottawa, ON, Canada
- Nancy Lamoureux – University of Ottawa at The Ottawa Hospital, Ottawa, ON, Canada
- Anne-Marie Duque – University of Ottawa at The Ottawa Hospital, Ottawa, ON, Canada
- David Ranger – University of North Carolina, Chapel Hill, NC
- Laurie Freeny – University of North Carolina, Chapel Hill, NC
- Linda Manor – University of North Carolina, Chapel Hill, NC
- Juliana Gitler – Duke University Medical Center, Durham, NC
- Ken Step – Duke University Medical Center, Durham, NC
- Robert Cordova – AIDS Healthcare Foundation Research Center, Los Angeles, CA
- Zenasda Vasques – AIDS Healthcare Foundation Research Center, Los Angeles, CA
- Jacob Pitt – Hartford-UCLA Medical Center, Torrance, CA
- Abbott Laboratories:
  - Kathy Shehan
  - Travis Yance
  - Cheryl Fahl

**BAGROUND**

Lopinavir (LPV) is an HIV protease inhibitor (PI) that is co-formulated with ritonavir (r), which functions as a pharmacokinetic enhancer. LPV/r is marketed as Kaletra®. The approved adult dose of LPV/r is 400/100 mg twice-daily (BID). In the U.S., a dose of LPV/r 800/200 mg once-daily (OD) is also approved for antiretroviral-naïve adults.

Treatment with combination antiretroviral therapy has had a profound impact in the management of HIV. However, antiretroviral therapy is sometimes associated with metabolic adverse effects including hypertriglyceridemia, lipaopathy and insulin resistance.1 Recent data have shown that hypertriglyceridemia and lipaopathy may be related at least in part to nucleoside reverse transcriptase inhibitor (NRTI) use, most notably stavudine.2 Since NRTIs may be associated with metabolic toxicities, it was hypothesized that use of an NRTI-sparing regimen may alleviate some metabolic toxicities. Previously, a pilot single-arm study of LPV/r and saquinavir (SQV) twice daily in 20 PI-naïve adults showed potent virologic suppression and immunologic improvements with this dual-boosted PI regimen.3 Study 384 is a pilot study designed to evaluate efficacy, safety and metabolic toxicities associated with two LPV/r-based regimens in antiretroviral-naïve subjects: dual PI, NRTI-sparing regimen of LPV/r plus SQV versus a nucleoside-containing regimen of LPV/r plus co-formulated zidovudine and lamivudine (ZDV/3TC). 48-week efficacy and safety results are reported.

**METHODS**

- Study 384 is a randomized, open-label study conducted at 6 sites in the U.S. and Canada.
- Subjects were antiretroviral-naïve with plasma HIV-1 RNA <400 copies/mL. There was no CD4 count restriction for enrollment.
- 30 subjects were randomized 1:1 to receive SQV 800 mg BID (n=16) or ZDV/3TC (300/150 mg) BID (n=14). All subjects received LPV/r soft gel capsules 400/100 mg BID (Figure 1).

![Study 384 Design](image)
RESULTS

Demographics

- Demographics and other baseline characteristics are summarized in Table 1. Notably, baseline CD4 cell count was statistically significantly lower in the LPV/r+ZDV/3TC group (p=0.045).

### Table 1. Study 384: Baseline Characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>LPV/r+SQV (n=16)</th>
<th>LPV/r+ZDV/3TC (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>16 (100%)</td>
<td>14 (100%)</td>
</tr>
<tr>
<td>White</td>
<td>10 (63%)</td>
<td>9 (64%)</td>
</tr>
<tr>
<td>Black</td>
<td>2 (13%)</td>
<td>2 (14%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2 (13%)</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>2 (13%)</td>
<td>3 (21%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (range)</td>
<td>42 (25–64)</td>
<td>40 (21–59)</td>
</tr>
<tr>
<td>Hepatitis B/C positive*</td>
<td>4 (25%)</td>
<td>5 (36%)</td>
</tr>
<tr>
<td>Baseline HIV-1 RNA (log_{10} copies/mL)</td>
<td>5.0 (3.7–5.9)</td>
<td>5.3 (4.1–6.2)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>269 (3–687)</td>
<td>120 (9–428)</td>
</tr>
<tr>
<td>CD4+ T-cell count (cells/mm³)**</td>
<td>6 (38%)</td>
<td>10 (71%)</td>
</tr>
</tbody>
</table>

* Hepatitis B surface antigen positive and/or hepatitis C virus antibody positive.
** Statistically significant difference between treatment groups, p<0.05.

### Subject Disposition

- 3 subjects in the LPV/r+SQV group discontinued prematurely prior to Week 48
  - 1 discontinued due to an adverse event (gastrointestinal symptoms)
  - 1 lost to follow-up
  - 1 due to virologic failure
- 5 subjects in the LPV/r+ZDV/3TC group discontinued prematurely prior to Week 48
  - 1 subject died (progressive multifocal leukoencephalopathy)
  - 3 discontinued due to adverse events (gastrointestinal symptoms [2], elevated liver function tests [1])
  - 1 withdrawn by investigator due to non-adherence

### Efficacy

- In the intent-to-treat (noncompleter=failure) and observed data analyses, a similar proportion of subjects achieved plasma HIV-1 RNA <50 copies/mL through 48 weeks of treatment (Figures 2–3).
- 3 subjects in the LPV/r+SQV group and 2 subjects in the LPV/r+ZDV/3TC group had HIV-1 RNA above 50 copies/mL at Week 48;
- In the intent-to-treat (noncompleter=failure) and observed data analyses, a similar proportion of subjects achieved plasma HIV-1 RNA <50 copies/mL at Week 48.
- Statistically significant mean increases in CD4+ T-cell count from baseline to each study visit were observed in both the LPV/r+SQV and the LPV/r+ZDV/3TC groups (Figure 4).

### Safety

- Moderately or severe adverse events of probable or possible relationship to study drug and occurring in >2 subjects in either treatment group are summarized in Table 2.
- No other grade 3/4 laboratory abnormalities occurred in >1 subject in either treatment group.

### Table 2. Study 384: Most Common Adverse Events of Moderate or Greater Severity

<table>
<thead>
<tr>
<th>Event</th>
<th>LPV/r+SQV (n=16)</th>
<th>LPV/r+ZDV/3TC (n=14)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>3 (19%)</td>
<td>3 (21%)</td>
<td>ns</td>
</tr>
<tr>
<td>Nausea</td>
<td>3 (19%)</td>
<td>4 (29%)</td>
<td>ns</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3 (19%)</td>
<td>3 (21%)</td>
<td>ns</td>
</tr>
</tbody>
</table>

* Grade 3/4 SGOT/AST and SGPT/ALT elevations (>5xULN) occurred in 1 subject in the LPV/r+SQV group and 2 subjects in the LPV/r+ZDV/3TC group (including 1 subject with a single transient grade 3 SGOT/AST and SGPT/ALT elevation). All 3 subjects were HIV/HCV co-infected, 1 additional subject in the LPV/r+ZDV/3TC group (HIV/HBV-co-infected) demonstrated a single transient grade 3 SGPT/ALT elevation at Week 32.

---

1. In both the LPV/r+SQV and LPV/r+ZDV/3TC arms, 100% of subjects had HIV-1 RNA levels <50 copies/mL at Week 48.
2. ns = not significant

---

1. In both the LPV/r+SQV and LPV/r+ZDV/3TC arms, 100% of subjects had HIV-1 RNA levels <50 copies/mL at Week 48. ns = not significant

---

1. In the LPV/r+SQV arm, 81% of subjects had HIV-1 RNA levels <80 copies/mL at Week 48.
**RESULTS**

**Demographics**
- Demographics and other baseline characteristics are summarized in Table 1. Notably, baseline CD4 cell count was statistically significantly lower in the LPV/r+ZDV/3TC group (p=0.045).

<table>
<thead>
<tr>
<th>Variable</th>
<th>LPV/r+SQV (n=16)</th>
<th>LPV/r+ZDV/3TC (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>16 (100%)</td>
<td>14 (100%)</td>
</tr>
<tr>
<td>White</td>
<td>10 (63%)</td>
<td>9 (64%)</td>
</tr>
<tr>
<td>Black</td>
<td>2 (13%)</td>
<td>3 (21%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2 (13%)</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>2 (13%)</td>
<td>3 (21%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>37 (25–68)</td>
<td>33 (25–67)</td>
</tr>
<tr>
<td>Hepatitis B/C positive*</td>
<td>4 (25%)</td>
<td>5 (36%)</td>
</tr>
<tr>
<td>Baseline HIV-1 RNA (log_{10} copies/mL)</td>
<td>5.0 (3.7–5.9)</td>
<td>5.3 (4.1–6.2)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>169 (3–687)</td>
<td>120 (9–428)</td>
</tr>
<tr>
<td>CD4 &lt;200 cells/mm²**</td>
<td>6 (358%)</td>
<td>10 (71%)</td>
</tr>
</tbody>
</table>

* Hepatitis B surface antigen positive and/or hepatitis C virus antibody positive.
** Statistically significant difference between treatment groups, p=0.045.

**Subject Disposition**
- 3 subjects in the LPV/r+SQV group discontinued prematurely prior to Week 48
  - 1 discontinued due to an adverse event (gastrointestinal symptoms)
  - 1 lost to follow-up
  - 1 due to virologic failure
- 5 subjects in the LPV/r+ZDV/3TC group discontinued prematurely prior to Week 48
  - 1 subject died (progressive multifocal leukoencephalopathy)
  - 3 discontinued due to adverse events (gastrointestinal symptoms [2], elevated liver function tests [1])
  - 1 withdrawn by investigator due to non-adherence

**Efficacy**
- In the intent-to-treat (noncompleter=failure) and observed data analyses, a similar proportion of subjects achieved plasma HIV-1 RNA <50 copies/mL through 48 weeks of treatment (Figures 2–3).
- 3 subjects in the LPV/r+SQV group and 2 subjects in the LPV/r+ZDV/3TC group had HIV-1 RNA levels >50 copies/mL at Week 48; however, HIV-1 RNA was <80 copies/mL for all 5 subjects.

**Safety**
- Moderate or severe adverse events of probable or possible relationship to study drug and occurring in >2 subjects in either treatment group are summarized in Table 2.
- No other grade 3/4 laboratory abnormalities occurred in >1 subject in either treatment group.
- After 4 weeks of treatment, significantly different mean changes from baseline were observed for fasting glucose (LPV/r+SQV: –5 mg/dL; LPV/r+ZDV/3TC: +13 mg/dL, p=0.025) and hematocrit (LPV/r+SQV: –0.6%; LPV/r+ZDV/3TC: –4.2%, p=0.003). However, these early differences were no longer apparent after 48 weeks of treatment (glucose: –3 mg/dL in each group, p=0.94; hematocrit: LPV/r+SQV: –0.1%; LPV/r+ZDV/3TC: –0.6%, p=0.65).
- Grade 3/4 SGOT/AST and SGPT/ALT elevations (>5xULN) occurred in 1 subject in the LPV/r+SQV group and 2 subjects in the LPV/r+ZDV/3TC group (including 1 subject with a single transient grade 3 SGOT/AST and SGPT/ALT elevation). All 3 subjects were HIV/HCV co-infected, 1 additional subject in the LPV/r+ZDV/3TC group (HIV/HBV co-infected) demonstrated a single transient grade 3 SGPT/ALT elevation at Week 32.

**Table 1. Study 384: Baseline Characteristics**

<table>
<thead>
<tr>
<th>Variable</th>
<th>LPV/r+SQV (n=16)</th>
<th>LPV/r+ZDV/3TC (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>14 (88%)</td>
<td>10 (71%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2 (13%)</td>
<td>7 (50%)</td>
</tr>
<tr>
<td>Black</td>
<td>2 (13%)</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>2 (13%)</td>
<td>3 (21%)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>269 (3–687)</td>
<td>120 (9–428)</td>
</tr>
<tr>
<td>CD4 &lt;200 cells/mm²**</td>
<td>6 (358%)</td>
<td>10 (71%)</td>
</tr>
</tbody>
</table>

**Figure 2. Study 384: HIV-1 RNA <50 copies/mL (ITT NC=F)**

**Figure 3. Study 384: HIV-1 RNA <50 copies/mL (observed data)**

**Figure 4. Study 384: Mean Change from Baseline in CD4+ T-cell Count**

<table>
<thead>
<tr>
<th>Drug-Related Adverse Events</th>
<th>LPV/r+SQV (n=16)</th>
<th>LPV/r+ZDV/3TC (n=14)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>3 (19%)</td>
<td>2 (14%)</td>
<td>ns</td>
</tr>
<tr>
<td>Nausea</td>
<td>3 (19%)</td>
<td>4 (29%)</td>
<td>ns</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3 (19%)</td>
<td>3 (21%)</td>
<td>ns</td>
</tr>
</tbody>
</table>
The approved adult dose of LPV/r is 400/100 mg twice-daily (BID). In the U.S., a dose of LPV/r 800/200 mg once-daily (QD) is also approved for antiretroviral-naive adults.

- No subjects were initiated on lipid lowering agents during the 48-week study period.
- Mean increases from baseline to Week 48 in total cholesterol (+60 mg/dL in each group) and triglycerides (+85 mg/dL in the LPV/r+SQV group and +64 mg/dL in the LPV/r+ZDV/3TC group) were similar between both groups. Most subjects remained at Grade 0–1 total cholesterol or triglyceride levels in both treatment groups through 48 weeks.
- Cholesterol increases included increases in both HDL cholesterol and LDL cholesterol. In the LPV/r+SQV group, the LDL-HDL cholesterol ratio was similar at baseline (3.5) and Week 48 (3.6); in the LPV/r+ZDV/3TC group, the ratio increased from 2.9 to 3.6. However, neither change was statistically significantly different from baseline, and the difference between groups was not significant.

**SUMMARY**

- In this pilot study, a regimen of LPV/r+SQV demonstrated similar efficacy based on the proportion of subjects with HIV-1 RNA <50 copies/mL and change from baseline in CD4+ T-cell counts through 48 weeks, compared to those receiving a standard triple regimen of LPV/r+ZDV/3TC.
- Similar frequencies and types of moderate or severe adverse events were noted between the 2 treatment groups.
- The only grade 3+ lab abnormalities noted in >1 subject were AST and ALT elevations, which occurred at similar rates in hepatitis coinfected subjects in both treatment groups.
- A similar degree of total cholesterol and triglyceride elevation was noted in both treatment groups through 48 weeks.
- No change in fasting glucose was noted in either treatment group in subjects treated for 48 weeks.

**CONCLUSIONS**

- The dual PI (NRTI-sparing) regimen of LPV/r plus saquinavir had similar efficacy and safety compared to a LPV/r-based standard combination antiretroviral regimen, with no more frequent lipid abnormalities and no elevation of fasting blood glucose over time.
- Although the small sample size limits the ability to discern differences between treatment groups, additional controlled studies of dual PI regimens may be considered to further assess possible metabolic benefits over the long-term in treatment-naive patients and the ability to treat NRTI-resistant HIV-1 in treatment-experienced patients. It may also be of greater interest to assess the potency, tolerability, and safety of dual PI combinations as new dosage forms become available.

**REFERENCES**

3. Staszewski S, Gallant JE, Pozniak AL et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral-naive patients: 36-week preliminary interim results. 10th CROI, Boston, MA, 2003; Poster 554c.

**ACKNOWLEDGMENTS**

Study 384 Subjects

Study 384 Clinical Site Coordinators:
- Man Ming Teil – Pacific Horizon Medical Group, San Francisco, CA
- Richard Gragert – University of Ottawa at The Ottawa Hospital, Ottawa, ON, Canada
- Nancy Lamoureux – University of Ottawa at The Ottawa Hospital, Ottawa, ON, Canada
- Anne-Marie Dugulubz – University of Ottawa at The Ottawa Hospital, Ottawa, ON, Canada
- David Reiner – University of North Carolina, Chapel Hill, NC
- Laurie Freway – University of North Carolina, Chapel Hill, NC
- Linda Marron – University of North Carolina, Chapel Hill, NC
- Julie Gnirn – Duke University Medical Center, Durham, NC
- Ken Steg – Duke University Medical Center, Durham, NC
- Robert Cordova – AIDS Healthcare Foundation Research Center, Los Angeles, CA
- Zenaida Vasquez – AIDS Healthcare Foundation Research Center, Los Angeles, CA
- Jacqui Pitt – Harrow-UCLA Medical Center, Torrance, CA
- Abbott Laboratories:
  - Kathy Shehan
  - Travis Yance
  - Cheryl Fahl

**METHODS**

- Study 384 is a randomized, open-label study conducted at 6 sites in the U.S. and Canada.
- Subjects were antiretroviral-naive with plasma HIV-1 RNA <400 copies/mL. There was no CD4 count restriction for enrollment.
- 30 subjects were randomized 1:1 to receive SQV 800 mg BID (n=16) or ZDV/3TC (300/150 mg) BID (n=14). All subjects received LPV/r soft gel capsules 400/100 mg BID (Figure 1).

**ACKNOWLEDGMENTS**

- Plasma HIV-1 RNA levels were measured every 4 weeks through Week 16, then every 8 weeks through Week 48 using Roche Amplicor HIV-1 Monitor Ultrasonic Quantitative PCR Assay, Version 1.5 (limit of quantification, 50 copies/mL).
- Fasting lipids and glucose were determined at Baseline, Week 24, and Week 48.
- Complete blood counts were performed every 4 weeks through Week 16, then every 8 weeks through Week 48.
- The proportion of subjects with HIV-1 RNA below 50 copies/mL was assessed using an intent-to-treat, noncomplerter-failure (ITT NC-F) method, in which missing values were considered failure unless the immediately preceding and following values were below 50 copies/mL. An observed data (OD) method was also used, in which missing values were excluded from the analysis.
- Cumulative incidence of adverse events through 48 weeks was summarized.